TLR7 and cancer: In addition, the results ofthis study conclude that the pH-degradable nanogel system furtherfacilitates a safe i.v. administration of highly immune stimulatingimidazoquinoline-type TLR7/8 adjuvants in combination with co-deliveredcancer-associated antigens and, thus, provides—in contrastto currently investigated antigen-free adjuvant treatments of tumors—opportunitiesto install cancer-specific immunity.